Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

Overview

About this study

The purpose of this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

- At least 18 years of age.

- Signed informed consent.

- Untreated, histologically confirmed adenocarcinoma of the prostate.

- High-risk or greater PC defined by National Comprehensive Cancer Network Guidelines
Version 1.202327 (clinical stage ≥T3a, or Grade Group ≥4, or PSA >20 ng/mL).

- Patients electing to undergo RP with PLND.

Exclusion Criteria:

- Administration of any high energy (>300 KeV) gamma-emitting radioisotope within 5
physical half-lives prior to Day 1.

- Known or expected hypersensitivity to 64Cu-SAR-bisPSMA or any of its components.

- Patients with known predominant small cell or neuroendocrine PC.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Eligibility last updated 12/15/23. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Robert Karnes, M.D.

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

Jacksonville, Fla.

Mayo Clinic principal investigator

Ephraim Parent, M.D., Ph.D.

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Jack Andrews, M.D.

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publications

Publications are currently not available